Capital’s Enigmatic Gambit: Dyne Therapeutics

According to the sacred scrolls of the SEC, filed for the period ending September 30, Saturn V Capital Management LP augmented its stake in Dyne Therapeutics by approximately 1.2 million shares. The fund’s position now commands a value of $33.8 million, a sum that, in the realm of 13F reportable assets, ranks as the fourth-largest in its portfolio. One might imagine the fund’s managers, like scribes in a cathedral of commerce, meticulously inscribing this act into the annals of fiscal history.







